Subscribe
Magazine
Videos
Advertise
About Us
Smart Water Summit
Wastewater Summit
Drinking Water
Smart Water
Asset Management
Water Utility Management
Water Reuse
Global Thought Leaders
Podcast
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
WaterWorld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
PDS Biotechnology Corporation - Common Stock
(NQ:
PDSB
)
1.290
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 22, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about PDS Biotechnology Corporation - Common Stock
< Previous
1
2
3
4
5
6
Next >
What's going on in today's after hours session
↗
March 20, 2026
Via
Chartmill
PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Q3 2025 Earnings Beat, Stock Surges 64% in Pre-Market
↗
November 13, 2025
PDS Biotech (PDSB) Q3 2025 earnings beat EPS estimates, sparking a major pre-market surge. The clinical-stage biotech also announced key progress for its lead cancer therapy.
Via
Chartmill
Topics
Earnings
Earnings Scheduled For November 13, 2025
↗
November 13, 2025
Via
Benzinga
A Look Ahead: PDS Biotechnology's Earnings Forecast
↗
November 12, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 11, 2025
Via
Benzinga
Insights into PDS Biotechnology's Upcoming Earnings
↗
August 12, 2025
Via
Benzinga
Insights Ahead: PDS Biotechnology's Quarterly Earnings
↗
May 13, 2025
Via
Benzinga
A Look at PDS Biotechnology's Upcoming Earnings Report
↗
March 26, 2025
Via
Benzinga
PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval
↗
October 30, 2025
The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial.
Via
Stocktwits
Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026
↗
October 30, 2025
Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids.
Via
Stocktwits
PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Narrower Q2 2025 Loss, Stock Rises on Clinical Progress
↗
August 13, 2025
PDS Biotechnology (PDSB) reported Q2 2025 EPS of -$0.21, beating estimates. Stock rose 8.13% pre-market as clinical progress, including ASCO presentations, boosts investor optimism. No revenue yet.
Via
Chartmill
PDSB Loss Improves as Costs Drop
↗
August 13, 2025
Via
The Motley Fool
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
July 16, 2025
Via
Benzinga
Uncovering Potential: PDS Biotechnology's Earnings Preview
↗
November 13, 2024
Via
Benzinga
Earnings Preview For PDS Biotechnology
↗
March 26, 2024
Via
Benzinga
Earnings Scheduled For August 13, 2025
↗
August 13, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
May 23, 2025
Via
Benzinga
PDS Biotechnology Stock In Spotlight On Better-Than-Feared 2024 Loss – Retail Stays Bearish
↗
March 27, 2025
The company said the reduced losses were primarily due to decreased operating expenses.
Via
Stocktwits
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
March 14, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Earnings Scheduled For May 14, 2025
↗
May 14, 2025
Via
Benzinga
Earnings Scheduled For March 27, 2025
↗
March 27, 2025
Via
Benzinga
Life Sciences Investor Forum Agenda Announced for March 13th
March 12, 2025
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
November 14, 2024
Via
Benzinga
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q2 2024
↗
August 13, 2024
PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q1 2024
↗
May 15, 2024
PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
March 27, 2024
Via
Benzinga
PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023
↗
March 27, 2024
PDSB stock results show that PDS Biotechnology beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Earnings Scheduled For November 14, 2024
↗
November 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
March 27, 2024
Via
Benzinga
Earnings Scheduled For March 27, 2024
↗
March 27, 2024
Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
